Skip to main content
SpringerLink
Log in

Epithelial ovarian cancer - more data, more questions?

Das epitheliale Ovarialkarzinom - mehr Daten, mehr Fragen?

  • main topic
  • Published:
Wiener Medizinische Wochenschrift Aims and scope Submit manuscript

Summary

This review provides an overview of latest insights in epithelial ovarian cancer biology. The current understanding of the origin and the complex heterogeneity are depicted, followed by an introduction to the latest therapeutic approaches. The role of the tumor microenvironment, the high potential to disseminate within the peritoneal cavity, and new molecular biological findings are summarized.

Zusammenfassung

Dieser Review gibt einen Überblick zu den neusten Erkenntnissen über Eierstockkrebs. Theorien über die Entstehung und die Heterogenität dieser Tumorentität sowie über die Bedeutung der Tumor-Mikroumgebung und die Charakteristika der peritonealen Aussaat werden beschrieben. Des Weiteren werden die aktuellen Therapieansätze dargestellt und neue molekularbiologische Ansätze diskutiert.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15. PubMed PMID: 21720365. Pubmed Central PMCID: 3163504.

    Article  Google Scholar 

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. PubMed PMID: 23335087.

    Article  PubMed  Google Scholar 

  3. Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;109(2):221–7. PubMed PMID: 17154394.

    Article  PubMed  Google Scholar 

  4. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl. 1):S161–92. PubMed PMID: 17161157.

    Google Scholar 

  5. Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1–5. PubMed PMID: 24219974.

    Article  PubMed  Google Scholar 

  6. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195(4):451–6. PubMed PMID: 11745677.

    Article  CAS  PubMed  Google Scholar 

  7. Bahar-Shany K, Brand H, Sapoznik S, Jacob-Hirsch J, Yung Y, Korach J, et al. Exposure of fallopian tube epithelium to follicular fluid mimics carcinogenic changes in precursor lesions of serous papillary carcinoma. Gynecol Oncol. 2014;132(2):322–7. PubMed PMID: 24355484.

    Article  CAS  PubMed  Google Scholar 

  8. Blaustein A. Peritoneal mesothelium and ovarian surface cells–shared characteristics. Int J Gynecol Pathol. 1984;3(4):361–75. PubMed PMID: 6511162.

    CAS  PubMed  Google Scholar 

  9. Sundfeldt K, Piontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, Brannstrom M, et al. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer. 1997;74(3):275–80. PubMed PMID: 9221804.

    Article  CAS  PubMed  Google Scholar 

  10. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211(1):26–35. PubMed PMID: 17117391.

    Article  CAS  PubMed  Google Scholar 

  11. Sehdev AS, Kurman RJ, Kuhn E, Shih Ie M. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol. 2010;23(6):844–55. PubMed PMID: 20228782. Pubmed Central PMCID: 2879438.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Erickson BK, Conner MG, Landen CN, Jr. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol. 2013;209(5):409–14. PubMed PMID: 23583217. Pubmed Central PMCID: 3937451.

  13. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43(5):420–32. PubMed PMID: 21716157.

  14. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164(5):1511–8. PubMed PMID: 15111296. Pubmed Central PMCID: 1615664.

  15. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198–208. PubMed PMID: 18698038.

  16. Yoshihara K, Tajima A, Komata D, Yamamoto T, Kodama S, Fujiwara H, et al. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis. Cancer Sci. 2009;100(8):1421–8. PubMed PMID: 19486012.

  17. Pils D, Hager G, Tong D, Aust S, Heinze G, Kohl M, et al. Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium. Cancer Sci. 2012;103(7):1334–41. PubMed PMID: 22497737.

  18. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49. PubMed PMID: 19474385.

  19. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53. PubMed PMID: 20818904.

  20. Polterauer S, Vergote I, Concin N, Braicu I, Chekerov R, Mahner S, et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. Int J Gynecol Cancer. 2012;22(3):380–5. PubMed PMID: 22266934.

  21. Harter P, Mahner S, Hilpert F, Runnebaum I, Ortmann O, Mustea A, et al. Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer. Geburtshilfe Frauenheilkd. 2013;73(3):221–3. PubMed PMID: 24771913.

  22. Siddiqui GK, Maclean AB, Elmasry K, Wong te Fong A, Morris RW, Rashid M, et al. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer. Angiogenesis. 2011;14(2):155–61. PubMed PMID: 21221762.

  23. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83. PubMed PMID: 22204724.

  24. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96. PubMed PMID: 22204725.

  25. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–6. PubMed PMID: 4938153.

  26. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–13. PubMed PMID: 12529460.

  27. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4. PubMed PMID: 17008531.

  28. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586–93. PubMed PMID: 17577038.

  29. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103. PubMed PMID: 21629244. Pubmed Central PMCID: 3137407.

  30. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222(4):350–66. PubMed PMID: 20927778. Pubmed Central PMCID: 3033700.

  31. Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, Al-Shibli K, et al. Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One. 2011;6(1):e14611. PubMed PMID: 21298041. Pubmed Central PMCID: 3029277.

  32. Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. 2003;94(11):1003–9. PubMed PMID: 14611679.

  33. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–55. PubMed PMID: 21483002.

  34. Liu F, Lang R, Zhao J, Zhang X, Pringle GA, Fan Y, et al. CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011;130(2):645–55. PubMed PMID: 21717105.

  35. Matkowski R, Gisterek I, Halon A, Lacko A, Szewczyk K, Staszek U, et al. The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res. 2009;29(7):2445–51. PubMed PMID: 19596912.

  36. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538–43. PubMed PMID: 16344461. Pubmed Central PMCID: 1311741.

  37. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22(3):393–402. PubMed PMID: 19060844.

  38. Shah CA, Allison KH, Garcia RL, Gray HJ, Goff BA, Swisher EM. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol. 2008;109(2):215–9. PubMed PMID: 18314181.

  39. Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009;58(3):449–59. PubMed PMID: 18791714.

  40. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360–5. PubMed PMID: 17360651. Pubmed Central PMCID: 1805580.

  41. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 2009;4(7):e6412. PubMed PMID: 19641607. Pubmed Central PMCID: 2712762.

  42. Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, et al. Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients—a study of the OVCAD consortium. BMC Cancer. 2013;13:422. PubMed PMID: 24044611. Pubmed Central PMCID: 3848589.

  43. Aust S, Bachmayr-Heyda A, Pils D, Zhao L, Tong W, Berger A, et al. Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer. Int J Gynecol Pathol. 2013;32(3):269–76. PubMed PMID: 23518910.

  44. Aust S, Bachmayr-Heyda A, Pateisky P, Tong D, Darb-Esfahani S, Denkert C, et al. Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer—a study of the OVCAD consortium. Mol Cancer. 2012;11:69. PubMed PMID: 22978347. Pubmed Central PMCID: 3533746.

  45. Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, et al. Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients—a study of the OVCAD consortium. Eur J Cancer. 2014;50(1):99–110. PubMed PMID: 24176298.

  46. Aust S, Auer K, Bachmayr-Heyda A, Denkert C, Sehouli J, Braicu I, et al. Ambivalent role of pFAK-Y397 in serous ovarian cancer—a study of the OVCAD consortium. Mol Cancer. 2014;13:67. PubMed PMID: 24655477. Pubmed Central PMCID: 3998046.

  47. O’Toole SA, Selinger CI, Millar EK, Lum T, Beith JM. Molecular assays in breast cancer pathology. Pathology. 2011;43(2):116–27. PubMed PMID: 21233672.

  48. Ween MP, Lokman NA, Hoffmann P, Rodgers RJ, Ricciardelli C, Oehler MK. Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. Int J Cancer. 2011;128(7):1570–84. PubMed PMID: 20521251.

  49. Said NA, Najwer I, Socha MJ, Fulton DJ, Mok SC, Motamed K. SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia. 2007;9(1):23–35. PubMed PMID: 17325741. Pubmed Central PMCID: 1803033.

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Molecular Oncology Group, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18–20, 1090, Vienna, Austria

    Stefanie Aust & Dietmar Pils

Authors
  1. Stefanie Aust
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dietmar Pils
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefanie Aust.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aust, S., Pils, D. Epithelial ovarian cancer - more data, more questions?. Wien Med Wochenschr 164, 479–486 (2014). https://doi.org/10.1007/s10354-014-0323-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10354-014-0323-8

Keywords

Schlüsselwörter

Search

Navigation